These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39504245)

  • 1. Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination.
    Clark JJ; Hoxie I; Adelsberg DC; Sapse IA; Andreata-Santos R; Yong JS; Amanat F; Tcheou J; Raskin A; Singh G; González-Domínguez I; Edgar JE; Bournazos S; Sun W; Carreño JM; Simon V; Ellebedy AH; Bajic G; Krammer F
    Cell Rep; 2024 Nov; 43(11):114922. PubMed ID: 39504245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination.
    Clark J; Hoxie I; Adelsberg DC; Sapse IA; Andreata-Santos R; Yong JS; Amanat F; Tcheou J; Raskin A; Singh G; González-Domínguez I; Edgar JE; Bournazos S; Sun W; Carreño JM; Simon V; Ellebedy AH; Bajic G; Krammer F
    bioRxiv; 2024 Mar; ():. PubMed ID: 38464151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines.
    Liang CY; Raju S; Liu Z; Li Y; Asthagiri Arunkumar G; Case JB; Scheaffer SM; Zost SJ; Acreman CM; Gagne M; Andrew SF; Carvalho Dos Anjos DC; Foulds KE; McLellan JS; Crowe JE; Douek DC; Whelan SPJ; Elbashir SM; Edwards DK; Diamond MS
    Nature; 2024 Jun; 630(8018):950-960. PubMed ID: 38749479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice.
    Becker W; Rebbani K; Duan Z; Valkov E; Bryant S; Ho M; Berzofsky JA; Olkhanud PB
    Sci Rep; 2024 Nov; 14(1):29609. PubMed ID: 39609527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo.
    Tsugawa Y; Furukawa K; Ise T; Takayama M; Ota T; Kuroda T; Shano S; Hashimoto T; Konishi H; Ishihara T; Sato M; Kamada H; Fukao K; Shishido T; Yoshikawa M; Takahashi T; Nagata S
    PLoS One; 2024; 19(12):e0300297. PubMed ID: 39621673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C
    J Virol; 2024 Jul; 98(7):e0052124. PubMed ID: 38874361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain.
    Guerra D; Radić L; Brinkkemper M; Poniman M; van der Maas L; Torres JL; Ward AB; Sliepen K; Schinkel J; Sanders RW; van Gils MJ; Beaumont T
    Hum Vaccin Immunother; 2024 Dec; 20(1):2388344. PubMed ID: 39165108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Reactive Antibody Responses to Coronaviruses Elicited by SARS-CoV-2 Infection or Vaccination.
    Lee RSH; Cheng SMS; Zhao J; Tsoi AYS; Lau KKM; Chan CHC; Li JKC; Hui DSC; Peiris M; Yen HL
    Influenza Other Respir Viruses; 2024 May; 18(5):e13309. PubMed ID: 38725111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
    Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y
    Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563
    [No Abstract]   [Full Text] [Related]  

  • 11. Using Experience Sampling Methodology to Capture Disclosure Opportunities for Autistic Adults.
    Love AMA; Edwards C; Cai RY; Gibbs V
    Autism Adulthood; 2023 Dec; 5(4):389-400. PubMed ID: 38116059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
    Alter G; Yu J; Liu J; Chandrashekar A; Borducchi EN; Tostanoski LH; McMahan K; Jacob-Dolan C; Martinez DR; Chang A; Anioke T; Lifton M; Nkolola J; Stephenson KE; Atyeo C; Shin S; Fields P; Kaplan I; Robins H; Amanat F; Krammer F; Baric RS; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH
    Nature; 2021 Aug; 596(7871):268-272. PubMed ID: 34107529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
    Collier AY; McMahan K; Yu J; Tostanoski LH; Aguayo R; Ansel J; Chandrashekar A; Patel S; Apraku Bondzie E; Sellers D; Barrett J; Sanborn O; Wan H; Chang A; Anioke T; Nkolola J; Bradshaw C; Jacob-Dolan C; Feldman J; Gebre M; Borducchi EN; Liu J; Schmidt AG; Suscovich T; Linde C; Alter G; Hacker MR; Barouch DH
    JAMA; 2021 Jun; 325(23):2370-2380. PubMed ID: 33983379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting.
    Seow J; Jefferson GCE; Keegan MD; Yau Y; Snell LB; Doores KJ
    PLoS Pathog; 2024 Nov; 20(11):e1012724. PubMed ID: 39556615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice.
    Yang H; Xie Y; Li S; Bao C; Wang J; Li C; Nie J; Quan Y
    Hum Vaccin Immunother; 2024 Dec; 20(1):2364519. PubMed ID: 38880868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualitative evidence synthesis informing our understanding of people's perceptions and experiences of targeted digital communication.
    Ryan R; Hill S
    Cochrane Database Syst Rev; 2019 Oct; 10(10):ED000141. PubMed ID: 31643081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare workers' informal uses of mobile phones and other mobile devices to support their work: a qualitative evidence synthesis.
    Glenton C; Paulsen E; Agarwal S; Gopinathan U; Johansen M; Kyaddondo D; Munabi-Babigumira S; Nabukenya J; Nakityo I; Namaganda R; Namitala J; Neumark T; Nsangi A; Pakenham-Walsh NM; Rashidian A; Royston G; Sewankambo N; Tamrat T; Lewin S
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD015705. PubMed ID: 39189465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insight into broadening SARS-CoV-2 neutralization by an antibody cocktail harbouring both NTD and RBD potent antibodies.
    Jiang W; Jiang Y; Sun H; Deng T; Yu K; Fang Q; Ge H; Lan M; Lin Y; Fang Z; Zhang Y; Zhou L; Li T; Yu H; Zheng Q; Li S; Xia N; Gu Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2406300. PubMed ID: 39470577
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.